At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
GSK Biologicals' HIV vaccine (732461) +1 morebiological
Likely dose
Chloroquine 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.
In Brief
A Phase 2 clinical trial evaluating GSK Biologicals' HIV vaccine (732461) and Chloroquine for AIDS. Completed, enrolled 28 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAIDS
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartDec 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedSep 7, 2009
Enrollment StartDec 1, 2009
Primary CompletionOct 4, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.8 years ago
Interventions
GSK Biologicals' HIV vaccine (732461)biological
1 dose intramuscular injection
Chloroquinedrug
One dose of 300 mg